Women and Risk of Type 2 Diabetes
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03870724|
Recruitment Status : Enrolling by invitation
First Posted : March 12, 2019
Last Update Posted : April 27, 2021
|Condition or disease|
|Type 2 Diabetes Mellitus|
The STORK-Groruddalen is a cohort study of 823 pregnant women. Participation rate was high due to facilitation for ethnic minorities and data collection at the local Health Centres, set up to study ethnic differences in health to inform prevention strategies to reduce these differences. The investigators have published many papers from this well charatertized cohort, about gestational diabetes and related health issues in pregnancy. Participants have agreed to be contacted for subsequent follow-up surveys.
The inivestigators are now planning a follow-up study of these woman during 2019-2022, to study trajectories for risk factors for type 2 diabetes and cardiovascular diseases such as BMI, blood pressure, lipids, behavioural factors, physical activity and mental health and other health issues. The investigators will collect selfreported information through questionnaires, perform clinical measurements and take blood samples and buccal swabs. Collecting updated information about a range of health outcomes for women in this cohort will, together with already collected data, enable us to study the development of risk factors for type 2 diabetes and cardiovascular diseases in a life course perspective.
|Study Type :||Observational|
|Estimated Enrollment :||500 participants|
|Official Title:||Women and Risk of Type 2 Diabetes|
|Actual Study Start Date :||August 27, 2019|
|Estimated Primary Completion Date :||December 2021|
|Estimated Study Completion Date :||December 2021|
- Type 2 diabetes [ Time Frame: 2 years ]Prevalence
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03870724
|University of Oslo, Faculty of Medicine, Institute of Health and Society|
|Oslo, Norway, 0316 Oslo|
|Principal Investigator:||Anne Karen Jenum||University of Oslo|